Lasa Supergenerics launches new product - Oxyclozanide

Capital Market 

Lasa Supergenerics has introduced another product - Oxyclozanide to its portfolio of product.

Oxyclozanide is an anthelmintic. It is used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle (especially buffalos in farm), sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit.

The total capacity would be 250 MT and The Company is committed to funding the required Capex through internal accruals. The production would start from August 2021.

The product is in huge demand and the management is confident of having a strong order book from the time production commences. The Company already has export approvals for several regions. Oxyclozanide would also be exported to these regions.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, June 09 2021. 11:26 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU